27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.

ENSC Insider Trading (Ensysce Biosciences)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $34,300.00
Insider Selling (Last 12 Months): $0.00

Ensysce Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Ensysce Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ensysce Biosciences Share Price & Price History

Current Price: $0.87
Price Change: Price Increase of +0.37 (74.30%)
As of 06/30/2022 05:00 PM ET

This chart shows the closing price history over time for ENSC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.

Ensysce Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/25/2022Lynn KirkpatrickCEOBuy70,000$0.49$34,300.00354,851View SEC Filing Icon  
See Full Table
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.

SEC Filings (Institutional Ownership Changes) for Ensysce Biosciences (OTCMKTS:ENSC)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ENSC by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Ensysce Biosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/17/2022Virtu Financial LLC24,630$28K0.0%N/A0.071%Search for SEC Filing on Google Icon
5/13/2022Renaissance Technologies LLC287,661$0.33M0.0%N/A0.899%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.122,353$0.14M0.0%-59.4%0.382%Search for SEC Filing on Google Icon
5/12/2022Anson Funds Management LP1,875,367$2.14M0.2%N/A5.859%Search for SEC Filing on Google Icon
5/12/2022BlackRock Inc.234,240$0.27M0.0%+41,654.0%0.732%Search for SEC Filing on Google Icon
5/9/2022Powell Investment Advisors LLC50,000$57K0.0%N/A0.156%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Securities LLC11,228$34K0.0%N/A0.046%Search for SEC Filing on Google Icon
11/15/2021Evergreen Capital Management LLC14,028$43K0.0%N/A0.058%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Ensysce Biosciences logo
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Read More on Ensysce Biosciences

Today's Range

Now: $0.87
Low: $0.50
High: $0.92

50 Day Range

MA: $0.66
Low: $0.42
High: $1.27

52 Week Range

Now: $0.87
Low: $0.40
High: $17.12

Volume

31,371,268 shs

Average Volume

945,475 shs

Market Capitalization

$30.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Ensysce Biosciences?

Ensysce Biosciences' top insider investors include:
  1. Lynn Kirkpatrick (CEO)
Learn More about top insider investors at Ensysce Biosciences.
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.